Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated interferon combined with acupoint-embedding for chronic hepatitis B
ChiCTR1900027949Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Nanjing
- Start
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pegylated interferon alpha in Chronic Hepatitis B (CHB) (2 arms), sponsored by The Second Hospital of Nanjing. Primary endpoint: HBsAg. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
pegylated interferon alpha
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR1900027949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027949.